GlassScriptPhysician profile
Tanvi V Joshi
NPI 1083107924
$2,218.96
in general payments reported to CMS, 2019-2025
25 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.85 · 2020: $16.91 · 2022: $382 · 2023: $918 · 2024: $630 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $340.35 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $328.48 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Regeneron Healthcare Solutions, INC. | $302.09 | 2022-2024 | Libtayo |
| Janssen Biotech, INC. | $153.93 | 2022-2024 | Erleada, Tecvayli, Akeega |
| Glaxosmithkline, LLC. | $134.12 | 2024-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $130.97 | 2022-2024 | Keytruda, Reblozyl, Lynparza |
| Incyte Corporation | $119.83 | 2023-2024 | Pemazyre, Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $82.30 | 2023-2025 | |
| Abbvie INC. | $75.57 | 2019-2022 | |
| Hologic Sales and Service, LLC | $69.41 | 2023 | Novasure, Acessa Provu System |
| Pharmaessentia USA Corporation | $61.42 | 2023-2024 | Besremi |
| Stemline Therapeutics INC. | $54.22 | 2023 | Orserdu |
| Pfizer INC. | $44.67 | 2024-2025 | |
| Tersera Therapeutics LLC | $39.92 | 2023-2025 | Zoladex |
| Genzyme Corporation | $37.62 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $35.50 | 2024-2025 | Perclot |
| Genentech USA, INC. | $32.84 | 2023-2024 | Lunsumio, Polivy, Tecentriq |
| Coopersurgical, INC. | $32.30 | 2019 | |
| Daiichi Sankyo INC. | $30.05 | 2022 | |
| Fennec Pharmaceuticals, INC. | $29.25 | 2025 | Fyarro |
| Dendreon Pharmaceuticals LLC | $19.80 | 2022 | |
| Adc Therapeutics America, INC. | $18.73 | 2023 | |
| Octapharma USA, INC. | $16.57 | 2022 | |
| Puma Biotechnology, INC. | $14.72 | 2023 | |
| Agios Pharmaceuticals, INC. | $14.30 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanvi Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.